Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 3/20 | 0.43 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.38 |
| ▸ | SERPINC1 | P01008 | 2/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.34 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15281445 | 1.00 | FGF1 (0.43) | FGF1HPSESERPINC1SSTR1SSTR2 | |
| SCHEMBL3382207 | 1.00 | FGF1 (0.43) | FGF1HPSESERPINC1SSTR1SSTR2 | |
| SCHEMBL19326323 | 1.00 | FGF1 (0.43) | FGF1HPSESERPINC1SSTR1SSTR2 | |
| SCHEMBL13151553 | 1.00 | FGF1 (0.43) | FGF1HPSESERPINC1SSTR1SSTR2 | |
| SCHEMBL14454731 | 1.00 | FGF1 (0.43) | FGF1HPSESERPINC1SSTR1SSTR2 | |
| SCHEMBL15281497 | 1.00 | FGF1 (0.43) | FGF1HPSESERPINC1SSTR1SSTR2 | |
| SCHEMBL15281498 | 1.00 | FGF1 (0.43) | FGF1HPSESERPINC1SSTR1SSTR2 | |
| SCHEMBL7636758 | 0.98 | FGF1 (0.45) | FGF1HPSESERPINC1SSTR1SSTR2 | |
| SCHEMBL7151360 | 0.98 | FGF1 (0.45) | FGF1HPSESERPINC1SSTR1SSTR2 | |
| SCHEMBL7146052 | 0.98 | FGF1 (0.45) | FGF1HPSESERPINC1SSTR1SSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227188-B2 | Enhancement of influenza gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110033859-A1 | RNAi INHIBITION OF INFLUENZA VIRUS REPLICATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-7772387-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579451-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | NT5C3B, DERA, DUT | FGF1 2008/4885HPSE 1501/4885SERPINC1 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.